Centre To Amend MDR To Include QMS Requirements For Certain Medical Devices

New Delhi:  The Central drug regulator may look at amending the Medical Device Rules (MDR), 2017 to include the Quality Management System (QMS) requirements for Class A non-sterile and non-measuring medical device, in order to ensure quality of these products.

The Drugs Technical Advisory Board (DTAB) in a recent meeting, has agreed with a proposal to amend the relevant sections of the Rules, which would mean an amendment in the Chapter IIIB, which was incorporated into the Rules through a notification in October, 2022.

The Board, in its 91st meeting held in August, was apprised that the MDR under Chapter III B specify the provisions for exemption of license to manufacture & import of the Class A (non-sterile and non-measuring) medical devices for marketing in the country.

While the Rule exempted licensing, the manufacturer or importer may obtain registration number by submitting the requisite information prescribed under sub-rule (2) of Rule 19H and sub-rule (2) of 19J of MDR, 2017, respectively.

It observed that the scope for conformance of QMS for manufacturing of such medical devices is not included in the rules. QMS is utmost important for manufacturing of medical devices to ensure that the product meets relevant standards and essential principles applicable for medical devices and the firm shall adhere with the QMS of fifth schedule of MDR, 2017, so that the safety and performance of medical devices will be ensured.

Hence, the undertaking stating that the manufacturing facility has complied the QMS as prescribed in the Fifth Schedule of MDR, 2017 may be included in the said rules, noted the Board.

“Accordingly, it was proposed that to amend rule 19H and 19J of Chapter IIIB of Medical Device Rules, 2017 to include the Quality Management System requirements for Class A (non-sterile and non-measuring) medical device,” said the DTAB.

The Board deliberated the matter and agreed for the proposed amendment under MDR, 2017, it said.

It may be noted that the Centre has notified the amendment of MDR, 2017, to exempt Class A (non-sterile and non-measuring) medical devices from import license and include the Chapter IIIB regarding the registration of these class of medical devices, in October, 2022. The Section 19H deals with information for registration to be uploaded by the industry, while 19J deals with the import of these class A medical devices.

The non-sterile and non-measuring medical devices include items such as gauze, instruments, scalpels, scissors, knives, etc.

Related Posts

US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

Hyderabad: The collaborative landscape of international pharmaceutical oversight reached a new milestone on May 5, 2026, as the Drugs Control Administration (DCA) of Telangana hosted the Second Regulatory Forum with…

Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

Spiritualism n Compassion being core of his Nature, Poor Patients may Hope for Best New Delhi: ‘Nishant’ literally meaning daybreak, Bihar may well hope to see a new Dawn of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

Six Women Develop Serious Complications After C-Section

Six Women Develop Serious Complications After C-Section

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

Indian Pharma Majors Plan to Invest in US

Indian Pharma Majors Plan to Invest in US

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr